FDA clearance gets a device to market. Post-market clinical data keeps it there and helps it grow. The evidence a device accumulates after launch, real-world outcomes, published studies, registry data, is among the most powerful tools a manufacturer has to drive adoption. Yet many manufacturers treat post-market data as a regulatory obligation rather than a distribution asset. That is a missed opportunity.
Post-market clinical data does more than satisfy regulators. It gives your distributor the evidence to win adoption conversations. Here is how to use it well.
Post-market data answers the question surgeons actually ask
A surgeon evaluating a device wants to know how it performs in the real world, not just in the pre-market trial. Post-market data answers that question directly. Real-world outcomes across a broad patient population carry more credibility than controlled trial data alone. When your distributor can show a surgeon how a device has performed across thousands of real cases, the adoption conversation gets easier.
Feed post-market evidence to your distribution partner
Post-market data only strengthens your distribution position if your distributor has it and can use it. Package the evidence in a form that a medical sales consultant can present in a surgeon conversation. Real-world outcome summaries, published post-market studies, and registry results all become tools your distributor uses to build the clinical case. Evidence that sits in a regulatory file does nothing for adoption.
Use post-market data to expand indications and applications
Strong post-market data can support the expansion of how a device is used and understood. As real-world evidence accumulates, it may reveal performance in patient populations or applications that the original launch did not emphasize. That evidence gives your distributor new conversations to have and new surgeon segments to reach. Post-market data is not just defensive. It opens growth.
How Synchrocare uses clinical evidence in the field
Synchrocare's medical sales consultants are trained to present clinical evidence credibly as part of every product conversation. The distribution model is built to put clinical data to work in the field, not just to store it. For manufacturers, that means post-market evidence supplied to Synchrocare becomes an active tool in adoption conversations across the territory.
The manufacturers who grow adoption over the full life of a device are the ones who keep building the evidence base and keep feeding it to their distribution partner. Post-market data is a growth asset. Treat it as one, and it strengthens your position in every facility your distributor serves.
To learn more about partnering with Synchrocare as your specialty distribution partner, visit www.synchrocare.com.